FK633: A potent and selective platelet GPIIb/IIIa antagonist

被引：7

作者：

Aoki, T

Harada, K

Seki, J

Tanaka, A

Takasugi, H

Motoyama, Y

机构：

[1] Fujisawa Pharmaceut Co Ltd, Med Biol Res Labs, Dept Pharmacol, Yodogawa Ku, Osaka 5328541, Japan

[2] Chem Res Labs, Osaka 5328541, Japan

来源：

CARDIOVASCULAR DRUG REVIEWS | 1999年 / 17卷 / 02期

关键词：

antiplatelet drugs; FK633; GPIIb/IIIa antagonists; thrombosis;

D O I：

10.1111/j.1527-3466.1999.tb00010.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：147 / 159

页数：13

共 53 条

[1] BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [J].

AGUIRRE, FV ;

TOPOL, EJ ;

FERGUSON, JJ ;

ANDERSON, K ;

BLANKENSHIP, JC ;

HEUSER, RR ;

SIGMON, K ;

TAYLOR, M ;

GOTTLIEB, R ;

HANOVICH, G ;

ROSENBERG, M ;

DONOHUE, TJ ;

WEISMAN, HF ;

CALIFF, RM .

CIRCULATION, 1995, 91 (12) :2882-2890

[2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[3]

Aoki T, 1998, THROMB HAEMOSTASIS, V79, P1184

[4] The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIb/IIIa antagonist [J].

Aoki, T ;

Cox, D ;

Senzaki, K ;

Seki, J ;

Tanaka, A ;

Takasugi, H ;

Motoyama, Y .

THROMBOSIS RESEARCH, 1996, 81 (04) :439-450

[5] Comparison of the antithrombotic effects of FK633, GPIIb/IIIa antagonist, and aspirin in a guinea pig thrombosis model [J].

Aoki, T ;

Cox, D ;

Senzaki, K ;

Seki, J ;

Tanaka, A ;

Takasugi, H ;

Motoyama, Y .

THROMBOSIS RESEARCH, 1998, 89 (03) :129-136

[6]

AOKI T, 1997, THROMB HAEMOST S, V78, P666

[7] Fibrin-rich and platelet-rich thrombus formation on neointima: Recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta [J].

Asada, Y ;

Hara, S ;

Tsuneyoshi, A ;

Hatakeyama, K ;

Kisanuki, A ;

Marutsuka, K ;

Sato, Y ;

Kamikubo, Y ;

Sumiyoshi, A .

THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) :506-511

[8]

Bednar B, 1996, CIRCULATION, V94, P571

[9] Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization [J].

Berkowitz, SD ;

Sane, DC ;

Sigmon, KN ;

Shavender, JH ;

Harrington, RA ;

Tcheng, JE ;

Topol, EJ ;

Califf, RM .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) :311-319

[10]

Byzova TV, 1998, THROMB HAEMOSTASIS, V80, P726

← 1 2 3 4 5 6 →